SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : dsco Discovery Laboratories
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wontgetfooledagin who wrote (8)4/16/1999 3:33:00 AM
From: Neenny  Read Replies (2) of 318
 
Wont,

As I read your post, I was concerned about the following statement:

The current surfaxin in use is a much more expensive drug made from cow urine

I do not intend to discredit the other information in your post, but your statement regarding Surfaxin is incorrect. Please let me clarify some information. Surfaxin is the name of the synthetic drug being tested by DSCO. The current non-synthetic drug is manufactured under the name Survanta. The intended use for both Surfaxin and Survanta, is as a replacement for a surfactant deficiency. It is also worth noting the currently used drug, Survanta, is derived from cows lungs.
You are completely correct when you say that the current drug is VERY expensive to produce. I believe the figure you tossed out regarding the cost per treatment to be fairly accurate. The synthetic drug will be much less costly to produce. It will make a marked improvement for the treatment of premature infant and Adult respiratory distress.

discoverylabs.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News